Education
About Us
Working with TipRanks
Follow Us
LENZ Therapeutics (LENZ)
NASDAQ:LENZ
LENZ Analyst Ratings
Strong Buy
6 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
LENZ Stock 12 Month Forecast
Average Price Target
$56.60
▲(111.83% Upside)
| Highest Price Target$62.00 | Average Price Target$56.60 | Lowest Price Target$52.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Citi
$52
Buy
94.61%
Upside
Reiterated
12/04/25
Piper Sandler
$67→$62
Buy
132.04%
Upside
Reiterated
12/01/25
H.C. Wainwright
$56
Buy
109.58%
Upside
Reiterated
11/06/25
TD Cowen
$60
Buy
124.55%
Upside
Initiated
11/05/25
William Blair
―
Buy
―
Reiterated
11/05/25
Promising Launch of LENZ Therapeutics' VIZZ: A Buy Opportunity Amidst Strong Initial Performance and Market Enthusiasm4:49 PM Research | Healthcare LENZ Therapeutics, Inc. (LENZ) $25.58 Market Value (M): $717 Biotechnology Lachlan Hanbury-Brown +1 312 364 8125 lhanbury- Third-Quarter Earnings; VIZZ Awareness as What’s new? VIZZ was approved by the FDA on July 31 (see our note here) and became commercially available at the start of October, with broad commercial availability expected by mid-November (see our note here). Since then, the sales team has been in the field detailing target ECPs and providing samples. Over 2,500 ECPs prescribed VIZZ in October, 40% multiple times, resulting in over 5,000 prescriptions filled.
Bank of America Securities
$53
Buy
98.35%
Upside
Reiterated
10/03/25
Leerink Partners
$36
Buy
34.73%
Upside
Reiterated
08/01/25
Strong Buy Recommendation for LENZ Therapeutics: Early Approval and Strategic Launch of VIZZ Eye DropsWe also believe the inclusion of the data demonstrating the durability of the effect for 10 hours will help to differentiate the product from the other presbyopia eye drops. The company has activated its branded commercial launch plan with its 88-member sales force and is planning to distribute samples to targeted optometrist offices no later than October. We also like the discount offered by the company on a 3-month supply (~16% discount/unit), as it should drive adoption of this product. Importantly, the company has $205M in cash, which includes recent upfront payments from the licensing agreements in Canada, so it’s well funded for launch.
Raymond James
$39→$40
Buy
49.70%
Upside
Reiterated
07/31/25
Mizuho Securities
$38
Buy
42.22%
Upside
Reiterated
03/20/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Citi
$52
Buy
94.61%
Upside
Reiterated
12/04/25
Piper Sandler
$67→$62
Buy
132.04%
Upside
Reiterated
12/01/25
H.C. Wainwright
$56
Buy
109.58%
Upside
Reiterated
11/06/25
TD Cowen
$60
Buy
124.55%
Upside
Initiated
11/05/25
William Blair
―
Buy
―
Reiterated
11/05/25
Promising Launch of LENZ Therapeutics' VIZZ: A Buy Opportunity Amidst Strong Initial Performance and Market Enthusiasm4:49 PM Research | Healthcare LENZ Therapeutics, Inc. (LENZ) $25.58 Market Value (M): $717 Biotechnology Lachlan Hanbury-Brown +1 312 364 8125 lhanbury- Third-Quarter Earnings; VIZZ Awareness as What’s new? VIZZ was approved by the FDA on July 31 (see our note here) and became commercially available at the start of October, with broad commercial availability expected by mid-November (see our note here). Since then, the sales team has been in the field detailing target ECPs and providing samples. Over 2,500 ECPs prescribed VIZZ in October, 40% multiple times, resulting in over 5,000 prescriptions filled.
Bank of America Securities
$53
Buy
98.35%
Upside
Reiterated
10/03/25
Leerink Partners
$36
Buy
34.73%
Upside
Reiterated
08/01/25
Strong Buy Recommendation for LENZ Therapeutics: Early Approval and Strategic Launch of VIZZ Eye DropsWe also believe the inclusion of the data demonstrating the durability of the effect for 10 hours will help to differentiate the product from the other presbyopia eye drops. The company has activated its branded commercial launch plan with its 88-member sales force and is planning to distribute samples to targeted optometrist offices no later than October. We also like the discount offered by the company on a 3-month supply (~16% discount/unit), as it should drive adoption of this product. Importantly, the company has $205M in cash, which includes recent upfront payments from the licensing agreements in Canada, so it’s well funded for launch.
Raymond James
$39→$40
Buy
49.70%
Upside
Reiterated
07/31/25
Mizuho Securities
$38
Buy
42.22%
Upside
Reiterated
03/20/25
Best Analysts Covering LENZ Therapeutics
1 Month
xxx
Success Rate
6/7 ratings generated profit
Average Return
+13.17%
initiated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 85.71% of your transactions generating a profit, with an average return of +13.17% per trade.
3 Months
xxx
Success Rate
6/7 ratings generated profit
Average Return
+23.31%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 85.71% of your transactions generating a profit, with an average return of +23.31% per trade.
1 Year
Success Rate
8/11 ratings generated profit
Average Return
+16.06%
reiterated a buy rating 4 months ago
Copying Marc Goodman's trades and holding each position for 1 Year would result in 72.73% of your transactions generating a profit, with an average return of +16.06% per trade.
2 Years
xxx
Success Rate
7/11 ratings generated profit
Average Return
+10.45%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 63.64% of your transactions generating a profit, with an average return of +10.45% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
LENZ Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
8
6
7
6
8
Buy
8
12
8
7
2
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
16
18
15
13
10
Each month's total comprises the sum of three months' worth of ratings.
LENZ Financial Forecast
LENZ Stock Forecast FAQ
What is LENZ’s average 12-month price target, according to analysts?
Based on analyst ratings, LENZ Therapeutics’s 12-month average price target is 56.60.
What is LENZ’s upside potential, based on the analysts’ average price target?
LENZ Therapeutics has 111.83% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is LENZ a Buy, Sell or Hold?
LENZ Therapeutics has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
What is LENZ Therapeutics’s price target?
The average price target for LENZ Therapeutics is 56.60. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $62.00 ,the lowest forecast is $52.00. The average price target represents 111.83% Increase from the current price of $26.72.
The highest analyst price target is $62.00 ,the lowest forecast is $52.00. The average price target represents 111.83% Increase from the current price of $26.72.
What do analysts say about LENZ Therapeutics?
LENZ Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
How can I buy shares of LENZ?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.